{
  "id": "8dc88f83c811b587",
  "title": "Opinion: STAT+: Excitement and wariness as FDA shifts to much more flexible cell and gene therapy oversight",
  "description": "These could arguably be the largest changes ever to cell and gene therapy oversight in the U.S.",
  "content": "These could arguably be the largest changes ever to cell and gene therapy oversight in the U.S.",
  "source": "STAT",
  "source_url": "https://www.statnews.com/2026/01/20/fda-cell-gene-therapy-cgt-oversight-flexible-system-risks/?utm_campaign=rss",
  "published_at": "2026-01-20T09:30:00+00:00",
  "fetched_at": "2026-01-21T00:24:36.527019+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "fda",
    "gene therapy"
  ],
  "location": null,
  "raw_data": {
    "title": "Opinion: STAT+: Excitement and wariness as FDA shifts to much more flexible cell and gene therapy oversight",
    "description": "These could arguably be the largest changes ever to cell and gene therapy oversight in the U.S.",
    "url": "https://www.statnews.com/2026/01/20/fda-cell-gene-therapy-cgt-oversight-flexible-system-risks/?utm_campaign=rss",
    "published": "2026-01-20T09:30:00+00:00",
    "source": "STAT"
  }
}